Andréa Lessa Benedet
YOU?
Author Swipe
View article: Plasma profiles of neurology-related proteins in at-risk mental state and first-episode psychosis: Associations with psychotic symptoms and cognitive performance
Plasma profiles of neurology-related proteins in at-risk mental state and first-episode psychosis: Associations with psychotic symptoms and cognitive performance Open
View article: Equivalence of the FCSRT and RAVLT to detect medial Temporal lobe atrophy and tauopathy
Equivalence of the FCSRT and RAVLT to detect medial Temporal lobe atrophy and tauopathy Open
View article: Glia inflammation and cell death pathways drive disease progression in preclinical and early AD
Glia inflammation and cell death pathways drive disease progression in preclinical and early AD Open
Accumulation of amyloid-β (Aβ) and neurofibrillary tangles (NFTs) are followed by the activation of glia cells and infiltration of peripheral immune cells that collectively accelerate neurodegeneration in preclinical AD models. Yet, the ro…
View article: Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegeneration
Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegeneration Open
INTRODUCTION Current literature presents conflicting results regarding the impact of neuroinflammation on Alzheimer's disease (AD)‐related neurodegeneration. While some studies suggest that neuroinflammation potentiates neurodegeneration, …
View article: Reversible tau hyperphosphorylation in hibernation: a blood biomarker and brain tissue study
Reversible tau hyperphosphorylation in hibernation: a blood biomarker and brain tissue study Open
View article: CSF total tau as a proxy of synaptic degeneration
CSF total tau as a proxy of synaptic degeneration Open
Cerebrospinal fluid (CSF) total tau (t-tau) is considered a biomarker of neuronal degeneration alongside brain atrophy and fluid neurofilament light chain protein (NfL) in biomarker models of Alzheimer’s disease (AD). However, previous stu…
View article: Plasma tau biomarkers for biological staging of Alzheimer’s disease
Plasma tau biomarkers for biological staging of Alzheimer’s disease Open
A blood biomarker-based staging system for Alzheimer’s disease (AD) could improve the diagnosis, prognosis and identification of individuals most likely to benefit from specific therapies. Here, using targeted mass spectrometry, we measure…
View article: Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno‐Sandwich Assay
Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno‐Sandwich Assay Open
INTRODUCTION Recent advancements in immunological methods accurately quantify biofluid biomarkers for Alzheimer's disease (AD) pathology. Despite progress, more biomarkers, ideally in blood, are needed for effective disease monitoring for …
View article: Exploring inflammation‐related protein expression and its relationship with TSPO PET in Alzheimer's disease
Exploring inflammation‐related protein expression and its relationship with TSPO PET in Alzheimer's disease Open
INTRODUCTION To understand the role of neuroinflammation in Alzheimer's disease (AD), we characterized immune‐related proteins in central and peripheral biofluids. METHODS Selection of participants from the Translational Biomarker of Aging…
View article: Biofluid-based staging of Alzheimer’s disease
Biofluid-based staging of Alzheimer’s disease Open
View article: Tau levels in platelets isolated from Huntington’s disease patients serve as a biomarker of disease severity
Tau levels in platelets isolated from Huntington’s disease patients serve as a biomarker of disease severity Open
Tau is a microtubule protein that is known to be hyperphosphorylated and to aggregate in several chronic neurodegenerative disorders. In many cases, in particular in Alzheimer’s disease, the degree of tau pathology has been demonstrated to…
View article: Evaluation of two plasma‐based proteotyping assays against <i>APOE</i> ε4 genotyping in a memory clinic setting: The Gothenburg H70 Clinical Studies
Evaluation of two plasma‐based proteotyping assays against <i>APOE</i> ε4 genotyping in a memory clinic setting: The Gothenburg H70 Clinical Studies Open
INTRODUCTION Apolipoprotein E ( APOE ) ε4 allele status is associated with an increased risk of Alzheimer's disease and should be determined prior to initiation of anti‐amyloid beta antibody treatment, because of increased risk of treatmen…
View article: Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum Open
Plasma phosphorylated tau (p-tau) biomarkers open unprecedented opportunities for identifying carriers of Alzheimer’s disease pathophysiology in early disease stages using minimally invasive techniques. Plasma p-tau biomarkers are believed…
View article: Plasma p‐tau<sub>217</sub> and neurofilament/p‐tau<sub>217</sub> ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration
Plasma p‐tau<sub>217</sub> and neurofilament/p‐tau<sub>217</sub> ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration Open
INTRODUCTION Plasma‐based biomarkers have shown promise for clinical implementation, but their accuracy in differentiating Alzheimer's disease (AD) from syndromes associated with frontotemporal lobar degeneration (FTLD) has yet to be fully…
View article: Tau spreading precedes the increase in tau load in Alzheimer’s disease
Tau spreading precedes the increase in tau load in Alzheimer’s disease Open
Tau pathology spreads and accumulates during Alzheimer’s disease (AD), but the relationship between these processes throughout disease progression remains unclear. We assessed the spatiotemporal dynamics of tau spreading and accumulation u…
View article: Stable brain PET metabolic networks using a multiple sampling scheme
Stable brain PET metabolic networks using a multiple sampling scheme Open
Interregional communication within the human brain is essential for maintaining functional integrity. A promising approach for investigating how brain regions communicate relies on the assumption that the brain operates as a complex networ…
View article: Identify biological Alzheimer’s disease using a novel nucleic acid–linked protein immunoassay
Identify biological Alzheimer’s disease using a novel nucleic acid–linked protein immunoassay Open
Blood-based biomarkers have been revolutionizing the detection, diagnosis and screening of Alzheimer’s disease. Specifically, phosphorylated-tau variants (p-tau181, p-tau217 and p-tau231) are promising biomarkers for identifying Alzheimer’…
View article: Comparison of Plasma p-tau217 and [ <sup>18</sup> F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia
Comparison of Plasma p-tau217 and [ <sup>18</sup> F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia Open
Our study provides evidence that plasma p-tau217 has strong discriminative accuracy for AD among patients with early-onset and/or atypical dementia assessed in specialized settings. Future work should replicate these findings in secondary …
View article: Astrocyte reactivity associates with tau phosphorylation and neurodegeneration before detectable amyloid‐β pathology
Astrocyte reactivity associates with tau phosphorylation and neurodegeneration before detectable amyloid‐β pathology Open
Background Aβ plaques are the first detectable signs of AD pathology. Our group recently demonstrated that the astrocyte activation marker, glial fibrillary acidic protein (GFAP), has a pivotal role in the association between Aβ burden and…
View article: Neuroinflammation potentiates the effect of amyloid‐β on longitudinal tau changes
Neuroinflammation potentiates the effect of amyloid‐β on longitudinal tau changes Open
Background It has been proposed that microglia release of proinflammatory factors reactive to amyloid plaques constitutes an early event leading to tau pathology. Here, we assessed how the rate of progression of tau‐PET and the rate of cha…
View article: Astrocyte reactivity associates with tau phosphorylation and neurodegeneration before detectable amyloid‐β pathology
Astrocyte reactivity associates with tau phosphorylation and neurodegeneration before detectable amyloid‐β pathology Open
Background Aß plaques are the first detectable signs of AD pathology. Our group recently demonstrated that the astrocyte activation marker, glial fibrillary acidic protein (GFAP), has a pivotal role in the association between Aß burden and…
View article: Phosphorylated tau is more closely associated with the spatial extent of tauopathy than with tau load
Phosphorylated tau is more closely associated with the spatial extent of tauopathy than with tau load Open
Background Recent evidence indicated that cognitive impairment is more closely associated with the spatial extent of tauopathy (SEOT) than with tau load. It remains unclear whether this is also true for other markers of Alzheimer’s disease…
View article: Neuroinflammation potentiates the effect of amyloid‐β on longitudinal tau changes
Neuroinflammation potentiates the effect of amyloid‐β on longitudinal tau changes Open
Background It has been proposed that microglia release of proinflammatory factors reactive to amyloid plaques constitutes an early event leading to tau pathology. Here, we assessed how the rate of progression of tau‐PET and the rate of cha…
View article: A machine learning approach to predict amyloid and tau positivity using clinical features
A machine learning approach to predict amyloid and tau positivity using clinical features Open
Background Screen failure due to amyloid negativity is yet a problem in clinical trials for anti‐amyloid drugs. In this context, clinical characteristics of patients presenting with cognitive decline may decrease the screen failure ratio b…
View article: Late‐life hypertension acts together with amyloid‐β pathology to promote memory loss
Late‐life hypertension acts together with amyloid‐β pathology to promote memory loss Open
Background Midlife hypertension (HTN) is a known risk factor for Alzheimer's disease (AD). However, it remains to be elucidated whether the effect of late‐life HTN is also present. Here, we aimed to assess the associations of late‐life HTN…
View article: Optimizing tau‐PET referrals in memory clinics through a blood biomarker workflow
Optimizing tau‐PET referrals in memory clinics through a blood biomarker workflow Open
Background Blood‐based biomarkers have demonstrated great promise for identifying biomarker‐confirmed Alzheimer's disease. We aimed to evaluate whether blood‐based biomarkers could optimize the referral of memory clinic patients to a tau‐P…
View article: A machine learning approach to predict tau positivity using clinical features in amyloid‐positive individuals
A machine learning approach to predict tau positivity using clinical features in amyloid‐positive individuals Open
Background Anti‐amyloid therapy appears to have an increased effect on reducing cognitive decline in amyloid‐ and tau‐positive individuals. However, clinical trials inclusion criteria require solely amyloid positivity. Herein, we developed…
View article: Hippocampal degeneration is associated with GFAP levels in individuals with vascular dementia independently of amyloidosis
Hippocampal degeneration is associated with GFAP levels in individuals with vascular dementia independently of amyloidosis Open
Background Vascular cognitive impairment/dementia (VD) is the second most prevalent cause of dementia following Alzheimer’s disease (AD). VD is characterized by the progression of white matter hyperintensity burden (WMH) and associated neu…
View article: Plasma proteomic profiling of mild cognitive impairment in two cohorts using the NULISAseq CNS Disease panel
Plasma proteomic profiling of mild cognitive impairment in two cohorts using the NULISAseq CNS Disease panel Open
Background Recently, the development of ultra‐sensitive immunoassays has allowed for the detection, in blood, of proteins related to the pathophysiology of Alzheimer’s disease (AD), with phosphorylated tau (p‐tau) being the most promising.…
View article: Plasma proteome profile of Lewy body pathology‐positive individuals
Plasma proteome profile of Lewy body pathology‐positive individuals Open
Background Lewy bodies (LB), the main hallmark of Parkinson’s disease (PD), are a frequent co‐pathology in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB). The varying extents of LB pathology in these disorders can influence d…